

EXHIBIT 26



Whitelaw Compliance Group, LLC.

Examination of Compliance Standards for Opioid Manufacturers and Distributors

Prepared For	Prepared By
<p>UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO, EASTERN DIVISION</p> <p><i>IN RE NATIONAL PRESCRIPTION OPIATE LITIGATION</i></p> <p>Case No. 18-OP-45132 (N.D. Ohio) MDL No. 2804 Case No. 17-md-2804 Judge Dan Aaron Polster</p>	<p>Dr. Seth B. Whitelaw</p> <p>President & CEO Whitelaw Compliance Group, LLC.</p> <p>April 15, 2019</p>

Table of Contents

PART I: QUALIFICATIONS, SCOPE & METHODOLOGY	1
1 QUALIFICATIONS	1
2 SCOPE & METHODOLOGY	2
2.1 SCOPE	2
2.2 METHODOLOGY	3
PART II: COMPLIANCE PROGRAM STANDARDS	4
3 UNDERSTANDING THE CONTEXT	4
3.1 GENERAL OVERVIEW OF COMPLIANCE	5
3.2 THE INTERLOCKING RELATIONSHIP BETWEEN SUSPICIOUS ORDER MONITORING, CONTROLLED SUBSTANCES, AND CORPORATE COMPLIANCE PROGRAMS	6
4 COMPLIANCE STANDARDS FOR CORPORATE COMPLIANCE PROGRAMS (1991 TO THE PRESENT)	7
4.1 FEDERAL SENTENCING GUIDELINES FOR ORGANIZATIONS	7
4.2 OIG COMPLIANCE PROGRAM GUIDANCE	11
4.3 AFFORDABLE CARE ACT	12
4.4 DOJ & OIG PROGRAM EFFECTIVENESS GUIDANCE	13
5 COMPLIANCE STANDARDS FOR CONTROLLED SUBSTANCES (1970 – THE PRESENT)	13
5.1 CONTROLLED SUBSTANCES ACT	13
5.2 DEA CONTROLLED SUBSTANCES REGULATIONS	15
5.3 DEA GUIDANCE ON CONTROLLED SUBSTANCES	16
5.3.1 CONTROLLED SUBSTANCES SECURITY MANUAL & SUSPICIOUS ORDER TASK FORCE (1997 TO 2004)	16
5.3.2 THE CHEMICAL HANDLER’S MANUAL	17
5.3.3 THE DEA INDUSTRY INITIATIVE	18
5.3.4 DEA LETTERS TO ALL REGISTRANTS (A.K.A. THE RANNAZZISI LETTERS) (2006 TO 2012)	19
5.3.5 MASTERS PHARMACEUTICAL CASE	20
5.4 INDUSTRY GUIDANCE	21
PART III: DEFINING WHAT GOOD LOOKS LIKE	23
6 APPLYING THE STANDARDS	23
6.1 GENERAL PRINCIPLES	24
6.1.1 CORPORATE COMPLIANCE PROGRAMS	24

6.1.2	SUSPICIOUS ORDER MONITORING PROGRAMS.....	26
6.2	COMPLIANCE CULTURE, ORGANIZATION & RESOURCES	27
6.2.1	ATTRIBUTES.....	28
6.3	WRITTEN STANDARDS & EDUCATION	29
6.3.1	ATTRIBUTES.....	30
6.4	MONITORING, AUDITING & INVESTIGATIONS	32
6.4.1	ATTRIBUTES.....	34
A.	Distributors	34
B.	Manufacturers.....	36
6.5	CORRECTIVE ACTIONS & RISK ASSESSMENTS	37
6.5.1	ATTRIBUTES.....	38
6.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT	39
6.6.1	DISCIPLINE.....	40
6.6.2	AVOIDING “BAD ACTORS” – EMPLOYEES OR CUSTOMERS.....	40
6.6.3	ATTRIBUTES.....	41
6.7	MANUFACTURER – PRESCRIBER RELATIONSHIP	42
7	MEASURING WHAT GOOD LOOKS LIKE	43
	PART IV: REPORT OVERVIEW	44
8	EXECUTIVE SUMMARY.....	44
8.1	GROUP 1 DISTRIBUTORS	44
8.2	GROUP 2 DISTRIBUTORS	45
8.3	MANUFACTURER GROUP	47
8.4	AN INTEGRATED ECOSYSTEM.....	48
A.	Euclid Family Pharmacy	49
B.	CVS Store 3322	51
C.	CVS Store 4800	52
	PART V: INDIVIDUAL COMPANY REVIEWS	53
9	McKESSON CORPORATION	53
9.1	BACKGROUND.....	53
9.2	EXECUTIVE SUMMARY	54
9.3	IMPACT	54
9.4	COMPANY COMMITMENT – COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	59

9.4.1	McKESSON'S CULTURE DEMONSTRATES A LACK OF COMMITMENT & SUPPORT FOR COMPLYING WITH ITS CONTROLLED SUBSTANCES OBLIGATIONS.....	60
9.4.2	McKESSON'S CONTENTION THAT THE SOM REQUIREMENTS WERE TOO VAGUE FOR IT TO DESIGN & OPERATE AN EFFECTIVE SOM PROGRAM IS SPECIOUS.....	64
9.4.3	McKESSON'S ORGANIZATIONAL DESIGN OF THE CONTROLLED SUBSTANCES PROGRAM REFLECTS A LACK OF SUPPORT FOR CONTROLLED SUBSTANCES COMPLIANCE EFFORTS.....	65
9.4.4	McKESSON FAILED TO RESOURCE THE CONTROLLED SUBSTANCES PROGRAM APPROPRIATELY.....	68
9.5	PROGRAM CORE - REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	70
9.5.1	McKESSON'S CODE OF CONDUCT DOES NOT MEET GENERALLY ACCEPTED COMPLIANCE STANDARDS.....	70
9.5.2	McKESSON'S STANDARDS OUTLINING ITS CONTROLLED SUBSTANCES PROGRAM WERE POORLY ORGANIZED AND DRAFTED UNDERMINING THE PRIMARY PURPOSE FOR CREATING STANDARD POLICIES AND PROCEDURES.	71
A.	Drug Operations Manual, Section 55	71
B.	Lifestyle Drug Monitoring Program	73
C.	Controlled Substances Monitoring Program.....	73
9.5.3	McKESSON'S <i>AD HOC</i> APPROACH TO CONTROLLED SUBSTANCES EDUCATION FOR ITS EMPLOYEES DID NOT AND STILL DOES MEET GENERALLY ACCEPTED COMPLIANCE STANDARDS.....	74
9.5.4	AS EARLY AS 2005, McKESSON KNEW ITS SOM PROGRAM WAS NOT IN COMPLIANCE WITH DEA REQUIREMENTS.....	76
9.5.5	McKESSON'S LDMP CONTINUED THE COMPANY'S NON-COMPLIANCE DUE TO POOR PROGRAM DESIGN AND IMPLEMENTATION.....	77
A.	Establishing the Thresholds	77
B.	The Daily Dosage Summary Report.....	78
C.	LDMP Escalation Process	79
9.5.6	UNDER THE CSMP, THRESHOLD SETTING COMBINED WITH OTHER TECHNIQUES RESULTED IN A SOM PROGRAM THAT CONTINUED TO BE NON-COMPLIANT WITH THE BASIC DEA REQUIREMENTS FOR CONTROLLED SUBSTANCES, AS WELL AS THE TERMS OF THE COMPANY'S 2008 SETTLEMENT AGREEMENT.	80
A.	Establishing Thresholds	81
B.	Threshold Buffers	82
C.	Threshold Disclosures.....	84
D.	Exceeding the Threshold (TCRs and Level 1-3 Review).....	86
E.	Customer Due Diligence or Level 1 Review	87
9.5.7	McKESSON'S INTERNAL AUDIT PROCESS WAS INEFFECTUAL AND NOT A REASONABLE CONTROL TO DETECT NON-COMPLIANCE.....	90
A.	2007 Report	91
B.	2010 Report	92
C.	2012 Report	92
9.5.8	McKESSON FAILED TO UNDERTAKE APPROPRIATE CORRECTIVE ACTIONS TO ENSURE ITS CONTROLLED SUBSTANCES PROGRAM WAS COMPLIANT WITH ITS REGULATORY OBLIGATIONS.	93
9.5.9	NO EVIDENCE WAS PRESENTED THAT McKESSON HAD A FORMAL RISK ASSESSMENT PROCESS DURING THE PERIOD.	94
9.6	PROGRAM CHANGES (2014 TO PRESENT).....	95

9.6.1	THE AGI ENGAGEMENT	95
A.	The Multiple-Threshold Model.....	95
B.	Non-Model Thresholds	96
9.6.2	McKESSON’S IMPLEMENTATION OF THE AGI MODEL	97
9.7	ACCOUNTABILITY - CONSISTENT ENFORCEMENT	98
9.7.1	DESPITE REPEATED BREACHES OF COMPANY POLICIES AND DEA SOM REQUIREMENTS, McKESSON FAILED TO DISCIPLINE THOSE INVOLVED.....	98
A.	Donald Walker	98
B.	Blaine Snider	99
C.	William de Gutierrez-Mahoney	99
9.7.2	McKESSON ALSO FAILED TO CONSISTENTLY TERMINATE CUSTOMERS FOUND IN REPEATED BREACH OF THE SOM REQUIREMENTS.	99
10	CARDINAL HEALTH, INC.....	100
10.1	BACKGROUND	100
10.2	EXECUTIVE SUMMARY	100
10.3	IMPACT	102
10.4	COMPANY COMMITMENT – COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	104
10.4.1	CARDINAL’S CULTURE IS MYOPICALLY FOCUSED ON INCREASING REVENUES AND CUTTING COST WHILE DOWNPLAYING THE IMPORTANCE OF ETHICS AND COMPLIANCE.	104
10.4.2	CARDINAL FAILED TO DESIGN AN ORGANIZATIONAL STRUCTURE WITH STRONG GOVERNANCE, MADE POOR STAFFING CHOICES AND WAS SLOW TO ADD RESOURCES TO THE SOM PROGRAM DEMONSTRATING A LACK OF COMMITMENT TO COMPLIANCE.....	106
10.5	PROGRAM CORE – REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	108
10.5.1	VIEWED HOLISTICALLY, THE CORE OF CARDINAL’S SOM PROGRAM DURING THE PERIOD RANGES FROM INCOMPLETE TO CONVOLUTED AND INCONSISTENT.	108
10.5.2	CARDINAL HEALTH FAILED TO UNDERSTAND THAT IT AND NOT THE DEA WAS RESPONSIBLE FOR MAINTAINING AN EFFECTIVE PROGRAM TO DETECT AND REPORT SUSPICIOUS ORDERS AND PREVENT DIVERSION.	109
10.5.3	CARDINAL’S EARLY CONTROLLED SUBSTANCES PROGRAM WAS NOT COMPLIANT WITH DEA REGULATORY REQUIREMENTS. ...	109
10.5.4	CARDINAL’S EARLY TRAINING EFFORTS WERE NOT FIT FOR COMPLIANCE PURPOSES.	112
10.5.5	CARDINAL’S SOM PROGRAM MODIFIED IN RESPONSE TO THE DEA ENFORCEMENT PROCEEDINGS FAILED TO MEET THE NECESSARY STANDARDS IN FIVE KEY AREAS: THRESHOLD SETTING, THRESHOLD INCREASES, DUE DILIGENCE, CUSTOMER MONITORING, AND INVESTIGATIONS.....	113
A.	Establishing Thresholds	114
B.	Threshold Events	116
C.	New Pharmacy Questionnaire	118
D.	Anti-Diversion Alert Signals	119
E.	On-site Investigations	122
F.	QRA SOM Customer Analytics General Work Instructions	123

10.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT.....	125
10.6.1	CARDINAL DOES NOT ENFORCE THE STANDARDS OF THE PROGRAM, AND THUS THERE IS NO REAL ACCOUNTABILITY FOR THE PROGRAM'S LACK OF EFFECTIVENESS.....	125
11	AMERISOURCEBERGEN CORPORATION.....	126
11.1	BACKGROUND	126
11.2	EXECUTIVE SUMMARY	128
11.3	IMPACT	128
11.4	COMPANY COMMITMENT – COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	131
11.4.1	THE “PRIVATE” VERSUS “PUBLIC” CULTURAL PARADOX WITHIN AMERISOURCEBERGEN HAMPERED ITS ABILITY TO CREATE AND MAINTAIN AN EFFECTIVE CONTROLLED SUBSTANCES COMPLIANCE PROGRAM.	131
11.4.2	AMERISOURCEBERGEN HAS FAILED TO OPTIMIZE ITS ORGANIZATIONAL CONNECTIONS BETWEEN ABC'S CONTROLLED SUBSTANCES PROGRAM AND ABC'S CORPORATE COMPLIANCE PROGRAM.	134
11.4.3	WHILE THE NUMBER OF PERSONNEL ASSIGNED TO AMERISOURCEBERGEN'S CSRA FUNCTION GREW OVER TIME, THE COMPANY DID NOT UTILIZE THOSE RESOURCES TO ITS BEST ADVANTAGE.	135
11.5	PROGRAM CORE – REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	138
11.5.1	PRIOR TO 2007, AMERISOURCEBERGEN'S TWO-PART CONTROLLED SUBSTANCES PROGRAM WAS AT BEST RUDIMENTARY, AND NOT COMPLIANT WITH DEA REGULATORY REQUIREMENTS.....	138
A.	Excessive Order Reports	138
B.	Manual Distribution Center Process	139
11.5.2	AMERISOURCEBERGEN'S ORDER MONITORING PROGRAM (“OMP”) BETWEEN 2007 AND 2016 WAS RENDERED INEFFECTIVE BY A COMBINATION OF POOR DESIGN AND INCONSISTENT APPLICATION.....	139
A.	Customer Size & Controlled Substances Ratio	142
B.	Rolling 30-Day Average.....	144
C.	OMP – Setting the Record Straight.....	145
D.	Low-Volume Accounts.....	147
11.5.3	AMERISOURCEBERGEN'S POST-SETTLEMENT CUSTOMER DUE DILIGENCE PROGRAM WAS INEFFECTIVE AS A RESULT OF POOR DESIGN AND INCONSISTENT APPLICATION.	148
A.	The CSRA Form 590	149
B.	“Verifying” CSRA 590 Data	150
C.	CSRA 590 Validation Project	151
D.	Process Not Followed.....	151
11.5.4	LIKE ITS ORDER MONITORING AND CUSTOMER DUE DILIGENCE PROCESSES, ABC'S INVESTIGATIONS PROCESS SUFFERED FROM POOR DESIGN AND LACK OF CONSISTENCY RENDERING IT INEFFECTIVE.....	152
11.5.5	ALTHOUGH ABC MADE ADDITIONAL PROGRAM MODIFICATION IN 2016, CSRA RETAINED THE ABILITY TO NEGATE THE NEW CONTROLS BY SIMPLY ISSUING THRESHOLD ADJUSTMENTS.	154
11.5.6	AMERISOURCEBERGEN'S TRAINING EFFORTS WERE INEFFECTIVE DUE TO AN APPROACH THAT WAS FRAGMENTED AND INCONSISTENT.	154

11.5.7	ABC’S FAILURE TO IMPLEMENT A FORMAL CORRECTIVE ACTION PROGRAM CONTRIBUTED TO THE COMPANY’S CONTINUED INEFFECTIVE CONTROLLED SUBSTANCES COMPLIANCE PROGRAM.....	157
11.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT.....	158
11.6.1	AMERISOURCEBERGEN DOES NOT ENFORCE THE STANDARDS OF THE PROGRAM, AND THUS THERE IS NO REAL ACCOUNTABILITY FOR THE PROGRAM’S LACK OF EFFECTIVENESS.	158
12	CVS HEALTH INC.	159
12.1	BACKGROUND	159
12.2	EXECUTIVE SUMMARY	159
12.3	IMPACT.....	161
12.4	COMPANY COMMITMENT – COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	162
12.4.1	CVS’ COMPLIANCE RECORD IS INDICATIVE OF A COMPANY THAT HAS A POOR COMMITMENT TO COMPLIANCE.....	162
12.4.2	CVS’ PENCHANT FOR COMPLEXITY AND COMPARTMENTALIZATION RESULTED IN A CONFUSING AND INEFFECTIVE ORGANIZATIONAL APPROACH TO CONTROLLED SUBSTANCES COMPLIANCE.	163
A.	CVS Entity Structure	163
B.	CVS Controlled Substances “Team”	164
C.	Integrating the Controlled Substances and Corporate Compliance Teams.....	165
12.4.3	CVS ALSO FAILED TO PROPERLY RESOURCE ITS CONTROLLED SUBSTANCES COMPLIANCE EFFORTS THROUGHOUT THE PERIOD. 166	
12.4.4	CVS’S TOLERANCE OF PROGRAM DOCUMENTATION THAT WAS EITHER NON-EXISTENT, INCOMPLETE OR INACCURATE IS INDICATIVE OF A COMPANY WITH A POOR COMPLIANCE CULTURE.....	167
12.5	PROGRAM CORE – REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	169
12.5.1	OVERALL CVS, FROM 2006 TO 2014, MAINTAINED AN INCOMPLETE AND DYSFUNCTIONAL ANTI-DIVERSION PROGRAM RELATED TO ITS DISTRIBUTION OF CONTROLLED SUBSTANCES.	169
A.	2006 – 2009	169
B.	2009 - 2011.....	171
C.	2011 to 2014.....	178
12.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT.....	182
12.6.1	CVS DID NOT HOLD EMPLOYEES ACCOUNTABLE FOR FAILING TO MAINTAIN AND OPERATE AN EFFECTIVE ANTI-DIVERSION PROGRAM. 182	
13	WALGREENS BOOTS ALLIANCE, INC.	183
13.1	BACKGROUND	183
13.2	EXECUTIVE SUMMARY	185
13.3	IMPACT.....	186
13.4	COMPANY COMMITMENT – COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	188
13.4.1	WALGREENS WAS SO FOCUSED ON THE RETAIL STORES THAT IT RESISTED AND ULTIMATELY FAILED TO ADOPT ANTI-DIVERSION MEASURES THAT WOULD REGULATE OR LIMIT A RETAIL STORE’S ABILITY TO OBTAIN UNCONTROLLED AMOUNTS OF OPIOID PRODUCTS.	188

13.4.2	FROM 2008 TO 2013, WALGREENS HAS FAILED TO INTEGRATE ITS CONTROLLED SUBSTANCE COMPLIANCE EFFORTS WITH THE CORPORATE COMPLIANCE PROGRAM IN ANY MEANINGFUL WAY.....	189
A.	Codes of Conduct	189
B.	Organization.....	191
13.4.3	WALGREEN’S FAILURES TO DESIGNATE A “HIGH-LEVEL” INDIVIDUAL OR GROUP WITH SOLE RESPONSIBILITY FOR CONTROLLED SUBSTANCES COMPLIANCE OR PROVIDE ENOUGH RESOURCES FOR THE GROUP CONTRIBUTED TO ITS INEFFECTIVE AND DYSFUNCTIONAL ANTI-DIVERSION PROGRAM.	192
A.	Prior to September 2012.....	192
B.	Formation of the Pharmaceutical Integrity Department.....	193
13.5	PROGRAM CORE – REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	194
13.5.1	FROM 1998 TO 2014, WALGREENS OPERATED AN ANTI-DIVERSION PROGRAM THAT LACKED THE FUNDAMENTAL CONTROLS OF EVEN A FOUNDATIONAL COMPLIANCE PROGRAM.	194
A.	Written Standards	194
B.	Detection & Corrections	198
C.	Audits	207
D.	Education.....	207
13.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT.....	208
13.6.1	WALGREENS FAILED TO ENFORCE THE STANDARDS OUTLINED IN THE PHARMACY CODE AND THUS THERE IS NO REAL ACCOUNTABILITY FOR THE PROGRAM’S LACK OF EFFECTIVENESS.....	208
14	MALLINCKRODT PHARMACEUTICALS	208
14.1	BACKGROUND	208
14.2	EXECUTIVE SUMMARY	210
14.3	IMPACT	212
14.4	COMPANY COMMITMENT - COMPLIANCE CULTURE, ORGANIZATION & RESOURCES.....	213
14.4.1	MALLINCKRODT’S PUBLIC COMMITMENT TO ITS VALUES OF BEING PATIENT-CENTRIC AND DEMONSTRATING INTEGRITY DOES NOT MIRROR ITS ACTUAL PRACTICE.....	213
A.	Code of Conduct.....	214
B.	Sales Representative Words and Actions.....	214
14.4.2	MALLINCKRODT FAILED TO APPROPRIATELY ORGANIZE AND STAFF ITS ANTI-DIVERSION PROGRAM RENDERING IT INEFFECTIVE. 216	
A.	Organizing and Staffing the Controlled Substances Compliance Group	216
B.	Using the Mallinckrodt Sales Force.....	217
14.5	PROGRAM CORE – REQUIREMENTS, EDUCATION, DETECTION & CORRECTIONS.....	218
14.5.1	MALLINCKRODT’S POOR DOCUMENTATION PRACTICES WERE AN IMPEDIMENT TO THE COMPANY’S EFFORTS TO ESTABLISH AN EFFECTIVE DIVERSION PROGRAM.....	218
14.5.2	MALLINCKRODT USED THE ARTIFICE OF “PECULIAR ORDERS” TO AVOID REPORTING SUSPICIOUS ORDERS TO THE DEA.....	221

14.5.3	THE MALLINCKRODT SUSPICIOUS ORDER PROGRAM WAS FLAWED BOTH IN ITS DESIGN AND IMPLEMENTATION RENDERING IT INEFFECTIVE TO DETECT SUSPICIOUS ORDERS.	223
A.	The Peculiar Order Algorithm and Due Diligence	223
B.	Howard Davis' Concerns	228
14.5.4	MALLINCKRODT FAILED TO EFFECTIVELY KNOW THEIR CUSTOMERS' CUSTOMER DESPITE HAVING ENOUGH INFORMATION TO CREATE A ROBUST SYSTEM TO DO SO.	230
A.	The SOM Customer Checklist (a k.a. SOM Customer Questionnaire)	231
B.	Chargeback Data	233
C.	Chargebacks & DEA Enforcement Actions	234
14.6	ACCOUNTABILITY - CONSISTENT ENFORCEMENT	236
14.6.1	EVEN IN THE FACE OF CREDIBLE EVIDENCE, MALLINCKRODT FREQUENTLY FAILED TO HOLD ITS DISTRIBUTORS ACCOUNTABLE FOR NOT HAVING ADEQUATE SOM PROGRAMS	236
14.6.2	MALLINCKRODT FAILED TO HOLD EMPLOYEES ACCOUNTABLE FOR BEING NON-COMPLIANT AND OUT OF SYNC WITH ITS VALUES.	237
APPENDICES		239
APPENDIX A: OPIOID PUBLIC HEALTH CRISIS – A BRIEF DISCUSSION		240
	Figure 1: Opioid Public Health Crisis – A Brief Discussion	240
	Figure 2: Oxycodone Distribution to Euclid by Distributor	242
APPENDIX B: APPLYING THE STANDARDS		243
	Figure 1: Table of Standard Elements Found in Policies and Procedures	243
	Figure 2: Controlled Substances Compliance	244
	Figure 3: Corporate Compliance	245
APPENDIX C: MCKESSON KEY FACTS AND FIGURES		246
	Figure 1: McKesson Self-Reported Data Points	246
	Figure 2: McKesson Program Overview (Circa 2015)	247
APPENDIX D: CARDINAL HEALTH KEY FACTS AND FIGURES		248
	Figure 1: Various Data Points	248
	Figure 2: Table 5 -Customer Release Percentage	249
APPENDIX E: AMERISOURCEBERGEN KEY FACTS AND FIGURES		250
	Figure 1: ABC 2009 Default Thresholds	250
	Figure 2: ABC Diversion Control Policies and Procedures (SOPs)	250
	Figure 3: West Virginia Suspicious Order Reports Submitted vs. Dosage Units Shipped	251
	Figure 4: Summit & Cuyahoga Suspicious Orders Reports Submitted	252
APPENDIX F: CVS KEY FACTS AND FIGURES		253
	Figure 1: CVS Entity Structure	253

Figure 2: CVS Logistics Organization.....	253
APPENDIX G: WALGREENS KEY FACTS AND FIGURES	254
Figure 1: Handling Suspicious Drug Orders	254
Figure 2: Review of CSR History.....	255
APPENDIX H: MALLINCKRODT KEY FACTS AND FIGURES.....	256
Figure 1: Controlled Substances Compliance SOPs.....	256
Figure 2: “Peculiar Orders” Definition Changes.....	257
APPENDIX I: LIST OF MATERIALS CONSIDERED.....	259
A. Defendant Production Documents.....	259
B. United States Code & Statutes	270
C. Code of Federal Regulations, Federal Register Notices & Other Regulatory Information	270
D. Cases, Settlements & Corporate Integrity Agreements	271
E. Articles, Websites & Other General Reference Materials.....	272
F. Defendant Discovery Responses; MDL No. 2804 <i>IN RE: National Prescription Opiate Litigation</i>	275
G. Corporate Witness Depositions.....	276
H. Third-Party Witness Depositions.....	277
I. Other Non-Publicly-Available Materials	278
APPENDIX J: EXPERT’S BACKGROUND	279
Resume	279
Publications List.....	283
Prior Testimony.....	286

PART III: Defining What Good Looks Like



6 Applying the Standards

As discussed in Part II, by the mid-1990s, the concept of “what good looks like” was established both in the context of corporate and controlled substances (a.k.a. anti-diversion) compliance. From that point forward it was clear that companies in the pharmaceutical industry, including manufacturers and distributors of opioid products, could develop effective internal controls to achieve the objectives to prevent and detect criminal conduct by an organization’s employees and agents working on behalf of the organization and to guard against theft and diversion of controlled substances.⁹⁴

In the U.S., the basic regulatory construct for pharmaceuticals, regardless of the agency, is to provide the industry with “what” is expected, but not dictate “how” those expectations are achieved. The “how” is left to the individual organizations to determine the best methods to comply. This approach is true in the case of the OIG, DEA, and even the FDA.⁹⁵

⁹⁴ See Appendix B, Figures 2 and 3 for diagrams outlining a controlled substances compliance program (a.k.a. anti-diversion program) and a corporate compliance program.

⁹⁵ See, e.g., U.S. Sentencing Commission, *Guidelines Manual*, § 8A.1.2, comment. (n. 3k) (Nov. 1991) [“FSGs 1991”]; J. Rannazzisi letters to All Registrants (Sep. 27, 2006, Feb. 7, 2007, Dec. 27, 2007 and Jun. 12, 2012) (These letters were not McKesson specific but sent to all DEA registrants), MCKMDL00478906, MCKMDL00615308, MCKMDL00478910, MCKMDL00449807 [“DEA (date) Letter”]; U.S. Food and Drug Admin., Center for Drug Evaluation and Research, *Facts About the Current Good Manufacturing Practices (CGMPs)*, <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm169105.htm>, (page last updated Jun. 25, 2018) (last accessed Dec. 8, 2018) (“The CGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures.”).